TBPH Q4 2021 Earnings — Theravance Biopharma, Inc. Revenue & Financial Results | Market Cap Arena

TBPHTheravance Biopharma, Inc.

$716M

Q4 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$15M-20.2% YoY

Gross Profit

-$16M-108.9% margin

Operating Income

-$56M-375.8% margin

Net Income

-$32M-214.3% margin

EPS (Diluted)

$-0.43

QoQ Revenue Growth

+13.3%

Cash Flow

Operating Cash Flow

-$42M

Free Cash Flow

-$43M

Stock-Based Comp.

$17M

Balance Sheet

Total Assets

$375M

Total Liabilities

$713M

Stockholders' Equity

-$339M

Cash & Equivalents

$90M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$15M	$19M	-20.2%
Gross Profit	-$16M	-$46M	+64.9%
Operating Income	-$56M	-$76M	+26.6%
Net Income	-$32M	-$58M	+45.2%

Revenue Segments

Viatris collaboration agreement

$12M81%

Collaborative revenue

$3M19%